HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Henry Ford Health System
Study ID
NCT03850366
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Hematological Malignancy

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Bortezomib — DRUG
    GVHD prophylaxis

Study Details

Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been shown to inhibit dendritic cells maturation and function and possesses a number of other favorable immunomodulatory effect that can prevent GVHD and help enhance immune reconstitution. this study is to assess the engraftment rate in patients with hematologic malignancies who need allogeneic stem cell transplant but do not have a suitable matched related or unrelated stem cell donor and will get T-cell replete HLA-Haploidentical allogeneic peripheral stem cell transplantation using post transplant Cyclophosphamide and bortezomib

Key Dates

Start date
Mar 8, 2016
Status verified
Feb 2026
Primary completion
Jan 1, 2028
Completion
Jan 1, 2028

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bortezomib

Primary Outcome Measure

engraftment rate [ Time Frame: within 30 days post transplant ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Henry Ford hospitalDetroitMichigan48202
shatha farhan
313-916-5002

Find similar trials in Detroit, MI

By research site
Henry Ford hospital· Detroit, MI

Related Studies